leisure time -WSS

leisure time

author：explore 2025-09-03 12:07:04 - browse：588

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Idaho abortion case may prompt more restrictions in other states

WSS

How the messy conversation about Dolly changed bioethics

Doulas covered by Medicaid under New York's new plan

The SUPPORT Act is critical to fighting the opioid crisis

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

HHS names first

House panel takes first step toward fixing drug shortages

hotspot

leisure time

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

As JPM 2024 winds down, some health tech firms project optimism

In age of alternative facts, a scholarly course on calling out crap

Why the drug industry's warnings on the IRA's impact fall short

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The unintended consequences of overturning Roe v. Wade

State Dept. review finds Biden bears some blame for Afghanistan failures

David Liu startup to focus on CRISPR delivery

How to save PrEP access — and even expand it

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Wikipedia

House panel takes first step toward fixing drug shortages

GSK to buy asthma

As JPM 2024 winds down, some health tech firms project optimism

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Neurocrine congenital adrenal hyperplasia trial succeeds

Designating disabled people as health disparity population is crucial

leisure time

hotspot

hotspot

Wikipedia